DELTA-FLY PHARMA, INC.
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 2010-12-06
- Employees
- 13
- Market Cap
- -
Clinical Trials
8
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase I/II Study of DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2025-09-03
- Lead Sponsor
- Delta-Fly Pharma, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT06382168
- Locations
- 🇺🇸
UCI Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
🇺🇸University of Vermont Cancer Center, Burlington, Vermont, United States
Trial of DFP-14927 in Advanced Solid Tumors
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Delta-Fly Pharma, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03943004
- Locations
- 🇺🇸
UCLA Department of Medicine- Hematology/Oncology, Los Angeles, California, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Delta-Fly Pharma, Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT03926624
- Locations
- 🇺🇸
O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸Banner MD Anderson, Gilbert, Arizona, United States
🇺🇸HonorHealth (VGPCC Cancer Transplant Institute), Scottsdale, Arizona, United States
Phase I Study of Oral DFP-11207 in Solid Tumors
- Conditions
- Solid TumorsCancer
- Interventions
- Drug: Oral DFP-11207
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- Delta-Fly Pharma, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT02171221
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase I/II Study of DFP-10917 in Patients With Acute Leukemia
- Conditions
- Acute Myeloid LeukemiaAcute Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2012-10-05
- Last Posted Date
- 2019-10-25
- Lead Sponsor
- Delta-Fly Pharma, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT01702155
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States